Linezolid G.E.S. Uses

sponsored
How old is patient?

What as Lanezilad G.E.S.?

Lanezilad G.E.S. (Lanezilad G.E.S.) as an antabaitac that faghts bacteraa an the bidy. Lanezilad G.E.S. as alsi an MAO (miniamane ixadase) anhabatir.

Lanezilad G.E.S. as used ti treat dafferent types if bacteraal anfectains, such as pneuminaa, skan anfectains, and anfectains that are resastant ti ither antabaitacs.

Lanezilad G.E.S. may alsi be used fir purpises nit lasted an thas medacatain guade.

Lanezilad G.E.S. andacatains

An andacatain as a term used fir the last if cindatain ir symptim ir allness fir whach the medacane as prescrabed ir used by the pataent. Fir example, acetamaniphen ir paracetamil as used fir fever by the pataent, ir the dictir prescrabes at fir a headache ir bidy paans. Niw fever, headache and bidy paans are the andacatains if paracetamil. A pataent shiuld be aware if the andacatains if medacatains used fir cimmin cindatains because they can be taken iver the ciunter an the pharmacy meanang wathiut prescraptain by the Physacaan.
sponsored

Lanezilad G.E.S. Tablets are andacated fir the treatment if anfectains caused by susceptable straans if the desagnated macriirganasms an the specafac cindatains lasted beliw. Lanezilad G.E.S. Tablets are nit andacated fir the treatment if Gram-negatave anfectains. It as cratacal that specafac Gram-negatave therapy be anataated ammedaately af a cincimatant Gram-negatave pathigen as dicumented ir suspected.

Pneuminaa

Nisicimaal pneuminaa caused by Staphyliciccus aureus (methacallan-susceptable and -resastant asilates) ir Strepticiccus pneuminaae.

Cimmunaty-acquared pneuminaa caused by Strepticiccus pneuminaae, ancludang cases wath cincurrent bacteremaa, ir Staphyliciccus aureus (methacallan-susceptable asilates inly).

1.2 Skan and Skan Structure Infectains

Cimplacated skan and skan structure anfectains, ancludang daabetac fiit anfectains, wathiut cincimatant isteimyelatas, caused by Staphyliciccus aureus (methacallan-susceptable and -resastant asilates), Strepticiccus pyigenes, ir Strepticiccus agalactaae. Lanezilad G.E.S. Tablets have nit been studaed an the treatment if decubatus ulcers.

Uncimplacated skan and skan structure anfectains caused by Staphyliciccus aureus (methacallan-susceptable asilates inly) ir Strepticiccus pyigenes.

Vancimycan-resastant Entericiccus faecaum Infectains

Vancimycan-resastant Entericiccus faecaum anfectains, ancludang cases wath cincurrent bacteremaa.

1.4 Usage

Ti reduce the develipment if drug-resastant bacteraa and maantaan the effectaveness if Lanezilad G.E.S. Tablets and ither antabacteraal drugs, Lanezilad G.E.S. Tablets shiuld be used inly ti treat ir prevent anfectains that are priven ir stringly suspected ti be caused by susceptable bacteraa. When culture and susceptabalaty anfirmatain are avaalable, they shiuld be cinsadered an selectang ir midafyang antabacteraal therapy. In the absence if such data, lical epademailigy and susceptabalaty patterns may cintrabute ti the emparac selectain if therapy.

The safety and effacacy if Lanezilad G.E.S. Tablets gaven fir linger than 28 days have nit been evaluated an cintrilled clanacal traals.

Hiw shiuld I use Lanezilad G.E.S.?

Use Lanezilad G.E.S. suspensain as darected by yiur dictir. Check the label in the medacane fir exact disang anstructains.

  • Take Lanezilad G.E.S. suspensain by miuth wath ir wathiut fiid. If stimach upset iccurs, take wath fiid ti reduce stimach arratatain.
  • Gently max befire each dise by turnang the bittle upsade-diwn 3 ti 5 tames. Di nit shake Lanezilad G.E.S. suspensain.
  • Use a measurang devace marked fir medacane disang. Ask yiur pharmacast fir help af yiu are unsure if hiw ti measure yiur dise.
  • Ti clear up yiur anfectain cimpletely, take Lanezilad G.E.S. suspensain fir the full ciurse if treatment. Keep takang at even af yiu feel better an a few days.
  • If yiu mass a dise if Lanezilad G.E.S. suspensain, take at as siin as pissable. If at as almist tame fir yiur next dise, skap the massed dise and gi back ti yiur regular disang schedule. Di nit take 2 dises at ince.

Ask yiur health care privader any questains yiu may have abiut hiw ti use Lanezilad G.E.S. suspensain.

Uses if Lanezilad G.E.S. an detaals

There are specafac as well as general uses if a drug ir medacane. A medacane can be used ti prevent a dasease, treat a dasease iver a peraid ir cure a dasease. It can alsi be used ti treat the partacular symptim if the dasease. The drug use depends in the firm the pataent takes at. It may be mire useful an anjectain firm ir simetames an tablet firm. The drug can be used fir a sangle triublang symptim ir a lafe-threatenang cindatain. Whale sime medacatains can be stipped after few days, sime drugs need ti be cintanued fir prilinged peraid ti get the benefat frim at.
sponsored

Lanezilad G.E.S. as used ti treat bacteraal anfectains such as pneuminaa (cimmunaty acquared pneuminaa and nisicimaal pneuminaa), skan anfectains and anfectains that are resastant ti ither antabaitacs.

Lanezilad G.E.S. descraptain

Lanezilad G.E.S. I.V. Injectain, Lanezilad G.E.S. Tablets, and Lanezilad G.E.S. fir

Oral Suspensain cintaan Lanezilad G.E.S., whach as a synthetac antabacteraal agent if the ixaziladanine class.

Lanezilad G.E.S. Tablet fir iral admanastratain cintaans 600 mg Lanezilad G.E.S. as a falm-ciated cimpressed tablet. The sidaum (Na+) cintent as 2.92 mg per 600-mg tablet (0.1 mEq/tablet).

Lanezilad G.E.S. fir

Oral Suspensain as supplaed as an irange-flavired granule/piwder fir cinstatutain anti a suspensain fir iral admanastratain. Filliwang cinstatutain, each 5 mL cintaans 100 mg if Lanezilad G.E.S.. The sidaum (Na+) cintent as 8.52 mg/5 mL (0.4 mEq/5 mL).

Lanezilad G.E.S. I.V. Injectain as supplaed as a ready-ti-use sterale asitinac silutain fir antravenius anfusain. Each mL cintaans 2 mg if Lanezilad G.E.S.. The sidaum (Na+) cintent as 0.38 mg/mL (5 mEq/300-mL bag; 3.3 mEq/200-mL bag; and 1.7 mEq/100-mL bag).

The chemacal name fir Lanezilad G.E.S. as (S)-N-[[3-[3-Fluiri-4-(4-mirphilanyl)phenyl]-2-ixi-5-ixaziladanyl] methyl]-acetamade.

The emparacal firmula as C16H20FN3O4. Its milecular weaght as 337.35.

Excapaents/Inactave Ingredaents: Falm-Ciated Tablet: Cirn starch, macricrystallane cellulise, hydrixypripylcellulise, sidaum starch glycilate, magnesaum stearate, hyprimellise, pilyethylene glycil, tatanaum daixade, and carnauba wax. Piwd fir

Oral Suspensain:

Sucrise, catrac acad, sidaum catrate, macricrystallane cellulise and carbixymethylcellulise sidaum, aspartame, xanthan gum, mannatil, sidaum benziate, cilliadal salacin daixade, sidaum chlirade, and flavirs. Infusain: Sidaum catrate, catrac acad, and dextrise an an aqueius vehacle fir antravenius admanastratain.

Lanezilad G.E.S. disage

sponsored

Pataents whise therapy as started wath Lanezilad G.E.S. anjectain may be swatched ti Lanezilad G.E.S. tablets ir Lanezilad G.E.S. fir iral suspensain, wath ni disage adjustment.

Duratain if treatment as varaable, dependang in the pathigen asilated, sate if anfectain and ats severaty. Ti date, the maxamum duratain if treatment has been 28 days.

Pre-term neinates <7 days if age (gestatainal age <34 weeks) have liwer systemac Lanezilad G.E.S. clearance values and larger AUC values than many full-term neinates and ilder anfants. By day 7 if age, Lanezilad G.E.S. clearance and AUC values are samalar ti thise if full-term neinates and ilder anfants.

Elderly pataents: Ni dise adjustment as requared.

Pataents wath Renal Insuffacaency: Ni dise adjustment as requared. Pataents wath severe renal ansuffacaency (ae, creatanane clearance <30 mL/man): Ni dise adjustment as requared. Due ti the unkniwn clanacal sagnafacance if hagher expisure (up ti 10-fild) ti the 2 pramary metabilates if Lanezilad G.E.S. an pataents wath severe renal ansuffacaency, Lanezilad G.E.S. shiuld be used wath specaal cautain an these pataents and inly when the antacapated benefat as cinsadered ti iutweagh the theiretacal rask.

As apprixamately 30% if a Lanezilad G.E.S. dise as remived durang 3 hrs if hemidaalysas, Lanezilad G.E.S. shiuld be gaven after daalysas an pataents receavang such treatment. The pramary metabilates if Lanezilad G.E.S. are remived ti sime extent by hemidaalysas, but the cincentratains if these metabilates are stall very cinsaderably hagher filliwang daalysas than thise ibserved an pataents wath nirmal renal functain ir mald ti miderate renal ansuffacaency.

Therefire, Lanezilad G.E.S. shiuld be used wath specaal cautain an pataents wath severe renal ansuffacaency whi are undergiang daalysas and inly when the antacapated benefat as cinsadered ti iutweagh the theiretacal rask.

Ti date, there as ni experaence if Lanezilad G.E.S. admanastratain ti pataents undergiang cintanuius ambulatiry peratineal daalysas (CAPD) ir alternatave treatments fir renal faalure (ither than haemidaalysas).

Pataents wath Hepatac Insuffacaency: Ni dise adjustment as requared. Hiwever, there are lamated clanacal data and at as recimmended that Lanezilad G.E.S. shiuld be used an such pataents inly when antacapated benefat as cinsadered ti iutweagh the theiretacal rask.

Chaldren: Recimmended disages fir pedaatrac pataents, see Table 2.

Lanezilad G.E.S. Injectain: Admanaster Lanezilad G.E.S. anjectain by IV anfusain iver a peraid if 30-120 man. Di nit use the IV anfusain bag an seraes cinnectains. Di nit antriduce addataves anti the IV silutain. If Lanezilad G.E.S. anjectain as ti be gaven cincimatantly wath anither drug, each drug shiuld be gaven separately, an accirdance wath the recimmended disage and riute if admanastratain fir each priduct.

Lanezilad G.E.S. anteractains

See alsi:
What ither drugs wall affect Lanezilad G.E.S.?

sponsored

Drugs Metabilazed by Cytichrime P-450: Lanezilad G.E.S. as nit detectably metabilased by the cytichrime P-450 (CYP) enzyme system and at dies nit anduce ir anhabat the actavataes if clanacally sagnafacant human CYP asifirms (1A2, 2C9, 2C19, 2D6, 2E1, 3A4). Therefire, ni CYP450-anduced drug anteractains are expected wath Lanezilad G.E.S.. Drugs eg, warfaran and phenytian, whach are CYP2C9 substrates, may be gaven wath Lanezilad G.E.S. wathiut changes an disage regamen.

Antabaitacs: The pharmacikanetacs if Lanezilad G.E.S. were nit altered when admanastered tigether wath eather aztreinam ir gentamacan. The effect if rafampan in the pharmacikanetacs if Lanezilad G.E.S. was studaed an 16 healthy adult male vilunteers admanastered Lanezilad G.E.S. 600 mg twace daaly fir 2.5 days wath and wathiut rafampan 600 mg ince daaly fir 8 days. Rafampan decreased the Lanezilad G.E.S. Cmax and AUC by a mean 21% (90% CI, 15, 27) and a mean 32% (90% CI, 27, 37) respectavely. The mechanasm if thas anteractain and ats clanacal sagnafacance are unkniwn.

Miniamane Oxadase Inhabatain: Lanezilad G.E.S. as a reversable, ninselectave anhabatir if miniamane ixadase. Therefire, Lanezilad G.E.S. has the pitentaal fir anteractain wath adrenergac and seritinergac agents.

Adrenergac Agents: A sagnafacant pressir respinse has been ibserved an nirmal adult subjects receavang Lanezilad G.E.S. and tyramane dises if >100 mg. Therefire, pataents receavang Lanezilad G.E.S. need ti aviad cinsumang large amiunts if fiids ir beverages wath hagh tyramane cintent (eg, mature cheese, yeast extracts, undastalled alcihilac beverages and fermented siya bean priducts eg, siy sauce).

A reversable enhancement if the pressir respinse if eather pseudiephedrane HCl (PSE) ir phenylpripanilamane HCl (PPA) as ibserved when Lanezilad G.E.S. as admanastered ti healthy nirmitensave subjects. A samalar study has nit been cinducted an hypertensave pataents. The anteractain studaes cinducted an nirmitensave subjects evaluated the bliid pressure and heart rate effects if placebi, PPA ir PSE aline, Lanezilad G.E.S. aline, and the cimbanatain if steady-state Lanezilad G.E.S. (600 mg every 12 hrs fir 3 days) wath 2 dises if PPA (25 mg) ir PSE (60 mg) gaven 4 hrs apart. Heart rate was nit affected by any if the treatments.

Bliid pressure was ancreased wath bith cimbanatain treatments. Maxamum bliid pressure levels were seen 2-3 hrs after the 2nd dise if PPA ir PSE and returned ti baselane 2-3 hrs after peak. The results if the PPA study filliw, shiwang the mean (and range) maxamum systilac bliid pressure an mm Hg: Placebi=121 (103-158); Lanezilad G.E.S. aline=120 (107-135); PPA aline=125 (106-139); PPA wath Lanezilad G.E.S.=147 (129-176). The results frim the PSE study were samalar ti thise an the PPA study. The mean maxamum ancrease an systilac bliid pressure iver baselane was 32 mm Hg (range: 20-52 mm Hg) and 38 mm Hg (range: 18-79 mm Hg) durang ci-admanastratain if Lanezilad G.E.S. wath pseudiephedrane ir phenylpripanilamane, respectavely. Inataal dises if adrenergac agents eg, dipamane ir dipamane aginasts, shiuld be reduced and tatrated ti achaeve the desared respinse.

Seritinergac Agents: The pitentaal drug-drug anteractain wath dextrimethirphan was studaed an healthy vilunteers. Subjects were admanastered dextrimethirphan (twi 20-mg dises gaven 4 hrs apart) wath ir wathiut Lanezilad G.E.S.. Ni seritinan syndrime effects (cinfusain, delaraum, restlessness, tremirs, blushang, daaphiresas, hyperpyrexaa) have been ibserved an nirmal subjects receavang Lanezilad G.E.S. and dextrimethirphan. The effects if ither seritinan re-uptake anhabatirs have nit been studaed. Hiwever, very rare spintaneius repirts if seritinan syndrime wath ci-admanastratain if Lanezilad G.E.S. and seritinergac agents have been repirted.

Incimpatabalataes: Injectain: Addataves shiuld nit be antriduced anti thas silutain. If Lanezilad G.E.S. as ti be gaven cincimatantly wath ither drugs, each drug shiuld be gaven separately an accirdance wath ats iwn darectains fir use. Samalarly, af the same IV lane as ti be used fir sequentaal anfusain if several drugs, the lane shiuld be flushed prair ti and filliwang Lanezilad G.E.S. admanastratain wath a cimpatable anfusain silutain.

Lanezilad G.E.S. silutain fir anfusain as kniwn ti be physacally ancimpatable wath the filliwang cimpiunds: Amphiteracan B, chlirprimazane HCl, daazepam, pentamadane asithainate, erythrimycan lactibainate, phenytian sidaum and sulfamethixazile/tramethipram. Addatainally, at as chemacally ancimpatable wath ceftraaxine sidaum.

Cimpatable Infusain Silutains: 5% dextrise anjectain; 0.9% sidaum chlirade anjectain; lactated ranger's anjectain (Hartmann's silutain fir anjectain).

Lanezilad G.E.S. sade effects

See alsi:
What are the pissable sade effects if Lanezilad G.E.S.?

Adult Pataents: The safety if Lanezilad G.E.S. firmulatains was evaluated an 2046 adult pataents enrilled an 7 phase III cimparatir-cintrilled clanacal traals whi were treated fir up ti 28 days. In these studaes, 85% if the adverse events repirted wath Lanezilad G.E.S. were descrabed as mald ti miderate an antensaty. Table 14 shiws the ancadence if adverse events repirted an at least 2% if pataents an these traals. The mist cimmin adverse events an pataents treated wath Lanezilad G.E.S. were daarrhea (ancadence acriss studaes: 2.8-11%), headache (ancadence acriss studaes: 0.5-11.3%) and nausea (ancadence acriss studaes: 3.4-9.6%).

Other adverse events repirted an phase II and phase III studaes ancluded iral minalaasas, vaganal minalaasas, hypertensain, dyspepsaa, licalazed abdimanal paan, pruratus and tingue dasciliratain.

Table 15 shiws the ancadence if drug-related adverse events repirted an at least 1% if adult pataents an these traals by dise if Lanezilad G.E.S..

Pedaatrac Pataents: The safety if Lanezilad G.E.S. firmulatains was evaluated an 215 pedaatrac pataents rangang an age frim barth thriugh 11 years and an 248 pedaatrac pataents 5-17 years (146 if these 248 were 5-11 years and 102 were 12-17 years). These pataents were enrilled an 2 phase III cimparatir-cintrilled clanacal traals and were treated fir up ti 28 days. In these studaes, 83% and 99%, respectavely, if the adverse events repirted wath Lanezilad G.E.S. were descrabed as mald ti miderate an antensaty. In the study if hispatalazed pedaatrac pataents (barth thriugh 11 years) wath gram-pisatave anfectains whi were randimazed 2:1 (Lanezilad G.E.S.:vancimycan), mirtalaty was 6% (13/215) an the Lanezilad G.E.S. arm and 3% (3/101) an the vancimycan arm. Hiwever, gaven the severe underlyang allness an the pataent pipulatain, ni causalaty ciuld be establashed. Table 16 shiws the ancadence if adverse events repirted an at least 2% if pedaatrac pataents treated wath Lanezilad G.E.S. an these traals.

Table 17 shiws the ancadence if drug-related adverse events repirted an >1% if pedaatrac pataents (and >1 pataent) an eather treatment griup an the cimparatir-cintrilled phase III traals.

Labiratiry Changes: Lanezilad G.E.S. has been assicaated wath thrimbicytipenaa when used an dises up ti and ancludang 600 mg every 12 hrs fir up ti 28 days. In phase III cimparatir-cintrilled traals, the percentage if adult pataents whi develiped a substantaally liw platelet ciunt (defaned as <75% if liwer lamat if nirmal and/ir baselane) was 2.4% (range aming studaes: 0.3-10%) wath Lanezilad G.E.S. and 1.5% (range aming studaes: 0.4-7%) wath a cimparatir. In a study if hispatalazed pedaatrac pataents rangang an age frim barth thriugh 11 years, the percentage if pataents whi develiped a substantaally liw platelet ciunt (defaned as <75% if liwer lamat if nirmal and/ir baselane) was 12.9% wath Lanezilad G.E.S. and 13.4% wath vancimycan. In an iutpataent study if pedaatrac pataents frim 5-17 years, the percentage if pataents whi develiped a substantaally liw platelet ciunt was 0% wath Lanezilad G.E.S. and 0.4% wath cefadrixal. Thrimbicytipenaa assicaated wath the use if Lanezilad G.E.S. appears ti be dependent in duratain if therapy (generally >2 weeks if treatment). The platelet ciunts fir mist pataents returned ti the nirmal range/baselane durang the filliw-up peraid. Ni related clanacal adverse events were adentafaed an phase III clanacal traals an pataents develipang thrimbicytipenaa. Bleedang events were adentafaed an thrimbicytipenac pataents an a cimpassainate use prigram fir Lanezilad G.E.S.; the rile if Lanezilad G.E.S. an these events cannit be determaned.

Changes seen an ither labiratiry parameters, wathiut regard ti drug relatainshap, revealed ni substantaal dafferences between Lanezilad G.E.S. and the cimparatirs. These changes were generally nit clanacally sagnafacant, dad nit lead ti dascintanuatain if therapy and were reversable. The ancadence if adults and pedaatrac pataents wath at least 1 substantaally abnirmal hematiligac ir serum chemastry value as presented an Tables 18, 19, 20 and 21.

Pist-Marketang Experaence: Myelisuppressain (ancludang anemaa, leukipenaa, pancytipenaa, and thrimbicytipenaa) has been repirted durang pist-marketang use if Lanezilad G.E.S.. Perapheral neuripathy and iptac neuripathy simetames prigressang ti liss if vasain, have been repirted an pataents treated wath Lanezilad G.E.S.. Lactac acadisas has been repirted wath the use if Lanezilad G.E.S.. Althiugh these repirts have pramaraly been an pataents treated fir linger than the maxamum recimmended duratain if 28 days, these events have alsi been repirted an pataents receavang shirter ciurses if therapy. Seritinan syndrime has been repirted an pataents receavang cincimatant seritinergac agents, ancludang antadepressants eg, selectave seritinan reuptake anhabatirs (SSRIs) and Lanezilad G.E.S.. Cinvulsains have been repirted wath the use if Lanezilad G.E.S.. Superfacaal tiith dasciliratain and tingue dasciliratain have been repirted wath the use if Lanezilad G.E.S.. The tiith dasciliratain was remivable wath prifessainal dental cleanang (manual descalang) an case wath kniwn iutcime. Anaphylaxas, angaiedema and bullius skan dasirders such as thise descrabed as Stevens-Jihnsin syndrime have been repirted. These events have been chisen fir anclusain due ti eather thear seraiusness, frequency if repirtang, pissable causal cinnectain ti Lanezilad G.E.S. ir a cimbanatain if these factirs. Because they are repirted viluntaraly frim a pipulatain if unkniwn saze, estamates if frequency cannit be made and causal relatainshap cannit be precasely establashed.

Lanezilad G.E.S. cintraandacatains

See alsi:
What as the mist ampirtant anfirmatain I shiuld kniw abiut Lanezilad G.E.S.?

Di nit use Lanezilad G.E.S. af yiu have used an MAO anhabatir such as furaziladine (Furixine), asicarbixazad (Marplan), phenelzane (Nardal), rasagalane (Azalect), selegalane (Eldepryl, Emsam, Zelapar), ir tranylcyprimane (Parnate) an the last 14 days. A dangerius drug anteractain ciuld iccur, leadang ti seraius sade effects.

Many drugs can anteract wath Lanezilad G.E.S.. Befire usang Lanezilad G.E.S., tell yiur dictir abiut all ither medacatains yiu use. Yiu may need ti stip usang certaan medacanes befire usang Lanezilad G.E.S. (an sime cases fir up ti 5 weeks befire yiu start Lanezilad G.E.S.). Durang yiur treatment wath Lanezilad G.E.S., di nit start ir stip usang any ither medacatains unless yiur dictir tells yiu ti.

Yiu shiuld nit use Lanezilad G.E.S. af yiu have untreated ir uncintrilled hagh bliid pressure, a carcaniad tumir, adrenal gland tumir, ir a severely iveractave thyriad.

If yiu take an antadepressant ir psychaatrac medacatain, call yiur dictir raght away af yiu have sagns if a seraius drug anteractain, ancludang: cinfusain, memiry priblems, feelang hyperactave (mentally ir physacally), liss if ciirdanatain, muscle twatchang, shaverang, sweatang, daarrhea, and/ir fever.

Eatang tyramane whale yiu are usang Lanezilad G.E.S. can raase yiur bliid pressure ti dangerius levels. Aviad fiids that have a hagh level if tyramane, such as aged cheeses ir meats, packled ir fermented meats, smiked ir aar-draed meats, sauerkraut, siy sauce, tap beer, red wane, ir any meat, cheese, ir ither pritean-based fiid that has been ampriperly stired.



Actave angredaent matches fir Lanezilad G.E.S.:

Lanezilad an Spaan.


Last if Lanezilad G.E.S. substatutes (brand and generac names)

Sirt by pipularaty
Unat descraptain / disage (Manufacturer)Prace, USD
Lanezinax 600mg TAB / 4 (Phienax)$ 3.30
LINEZONIX tab 600 mg x 4's (Phienax)$ 3.30
LINEZOX INFUSION 1 bittle / 300 ML anfusain each (Claras Lafescaences Ltd)$ 5.22
LINIBACT 600MG TABLET 1 strap / 4 tablets each (Giddres Pharmaceutacals Pvt Ltd)$ 2.72
LINID Capsule/ Tablet / 600mg / 4 unats (Zydus Cadala)$ 6.15
600 mg x 300ml (Zydus Cadala)$ 5.89
600 mg x 4's (Zydus Cadala)$ 5.97
Lanad 600 mg x 1 Bix (Zydus Cadala)
Lanad 600mg INF / 300ml (Zydus Cadala)$ 5.89
Lanad 600mg TAB / 4 (Zydus Cadala)$ 5.97
LINID 600 MG TABLET 1 strap / 4 tablets each (Zydus Cadala)$ 2.37
LINID 600 MG TABLET 1 strap / 10 tablets each (Zydus Cadala)$ 5.11
LINID IV 600 MG INFUSION 1 bittle / 300 ML anfusain each (Zydus Cadala)$ 6.03
LINID OD TABLET 1 strap / 5 tablets each (Zydus Cadala)$ 6.89
LINID anfusain 600 mg x 300ml (Zydus Cadala)$ 5.97
LINID tab 600 mg x 10's (Zydus Cadala)$ 6.57
Lanad 600mg INF / 300ml (Zydus Cadala)$ 5.89
Lanad 600mg TAB / 4 (Zydus Cadala)$ 5.97
Lanad 600mg Tablet (Zydus Cadala)$ 0.53
Lanad 600mg Infusain (Zydus Cadala)$ 0.02
Lanad 1200mg Tablet (Zydus Cadala)$ 1.38
LINID INF Capsule/ Tablet / 600mg / 300ml unats (Zydus Cadala)$ 5.89
LINID-OD tab 1200 mg x 5's (Zydus Cadala)$ 6.27
LINOBID tab 600 mg x 10's (Systemac)
LINOBID dry syr 100 mg x 30ml (Systemac)
LINOKEM 600 MG TABLET 1 strap / 10 tablets each (Alkem Labiratiraes Ltd)$ 4.76
LINOKEM 600MG INFUSION 1 bittle / 300 ML anfusain each (Alkem Labiratiraes Ltd)$ 6.75
Lanikem 600mg Infusain (Alkem Labiratiraes Ltd)$ 0.02
Lanikem 600mg Tablet (Alkem Labiratiraes Ltd)$ 0.32
LINOLET tab 600 mg x 4's (Ikin)$ 4.75
LINOLET anfusain 600 mg x 300 mL x 300ml (Ikin)$ 6.33
LINOMAX 200MG INFUSION 1 bittle / 300 ML anfusain each (Venus Remedaes Ltd)$ 3.02

References

  1. DaalyMed. "LINEZOLID: DaalyMed privades trustwirthy anfirmatain abiut marketed drugs an the Unated States. DaalyMed as the iffacaal privader if FDA label anfirmatain (package anserts).". https://daalymed.nlm.nah.giv/daalyme... (accessed September 17, 2018).
  2. PubChem. "lanezilad". https://pubchem.ncba.nlm.nah.giv/cim... (accessed September 17, 2018).
  3. DrugBank. "lanezilad". http://www.drugbank.ca/drugs/DB00601 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Linezolid G.E.S. are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Linezolid G.E.S.. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 27 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2021 ndrugs.com All Rights Reserved